Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Context: Weight loss remains one of the most important arms in obese patients with polycystic ovary syndrome (PCOS). Further studies are needed to identify the best treatment. Objective: To evaluate the effects of exenatide (EXE) on reproductive and metabolic function in overweight/obese (OW/OB) PCOS. Design: This is a 24‐week open‐label prospective, randomized, clinical study. Patients and Measurements: This study randomized 176 OW/OB women diagnosed with PCOS to receive either EXE 10 μg BID (n = 88) or metformin (MET) 1000 mg BID (n = 88) for the first 12 weeks. Then all patients were treated with MET alone during the second 12 weeks. We observed metabolic parameters at 0 and 12 weeks, and then tracked the rate of pregnancy during the second 12 weeks. Results: After the first 12 weeks of intervention, compared with MET, subjects who received EXE had significantly decreased weight (4.29 ± 1.29 kg vs 2.28 ± 0.55 kg, P < .001) and total fat% (4.67 ± 0.09% vs 1.11 ± 0.32%, P < .001), improved the homeostasis model of assessment for insulin resistance (1.30 ± 0.58 vs 0.59 ± 0.12, P < .001) and increased the menstrual frequency ratio (0.62 ± 0.12 vs 0.37 ± 0.01, P < .001). During the second 12 weeks, the rate of natural pregnancy of EXE‐treated patients was significantly higher than MET‐treated patients (43.60% vs 18.70%, P < .05). Conclusions: Short‐term EXE therapy was linked to significant weight loss and central adiposity reduction, which may further explain the improvements in insulin resistance, inflammatory marker and menstrual cycle, which may contribute to increasing pregnancy rates in OW/OB women with PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Moran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269
Research works printed but not linked: 21
- 10.1016/j.bpobgyn.2004.05.005 · DOI
- 10.1093/oxfordjournals.humrep.a019512 · DOI · Paper page
- 10.1210/jc.2004-2283 · DOI · Paper page
- 10.1210/endo.140.11.7143 · DOI · Paper page
- 10.1159/000446951 · DOI
- 10.2337/dc06-0864 · DOI
- 10.1016/j.obmed.2017.06.003 · DOI
- Huang Zhaosui LLY, 2015, Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity, Chin J Diabetes Mellitus, 7, 437
- 10.1530/EJE-13-0797 · DOI · Paper page
- 10.1080/gye.15.2.142.149 · doi:10.1080/gye.15.2.142.149 · Paper page
- 10.1210/jc.80.4.1283 · DOI · Paper page
- 10.1210/jc.2002-021688 · DOI · Paper page
- 10.1530/REP-09-0568 · DOI · Paper page
- 10.1097/GCO.0b013e32832aee96 · DOI · Paper page
- 10.1016/j.soard.2005.02.008 · DOI · Paper page
- 10.1016/S1472-6483(10)61179-0 · DOI
- 10.1210/er.2014-1020 · DOI · Paper page
- 10.1161/CIRCHEARTFAILURE.112.000115 · DOI
- 10.1093/humrep/deh609 · DOI · Paper page
- Sangraula H, 2009, Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome, JNMA J Nepal Med Assoc, 48, 335
- 10.1016/j.ecl.2015.07.006 · DOI
Cited by
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
“Then all patients were treated with metformin alone during the second 12 weeks (98).”
BackgroundMetabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204
Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J., & Bellanger, D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.04.027 · Cited by 182
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Jensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
“12) (44) PCOS& OB 12week Exenatide 10ug bid Met 1000 mg bid 178 27.”
Nishiyama, Y., Hasegawa, T., Fujita, S., Iwata, N., Nagao, S., Hosoya, T., Inagaki, K., Wada, J., & Otsuka, F. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.11.004 · Cited by 43
Sun, Z., Li, P., Wang, X., Lai, S., Qiu, H., Chen, Z., Hu, S., Yao, J., & Shen, J. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1484321 · Cited by 37
“GLP-1RAs treatment, it was also observed that the level of androgens was modestly decreased and the menstrual frequency was increased [8, 11, 12].”
BackgroundHow to manage weight loss in women with obesity and PCOS seeking fertility?
Hazlehurst, J. M., Singh, P., Bhogal, G., Broughton, S., & Tahrani, A. A. (2022) · Clinical Endocrinology · doi:10.1111/cen.14726 · Cited by 37
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
Ma, R., Ding, X., Wang, Y., Deng, Y., & Sun, A. (2021) · Medicine · doi:10.1097/md.0000000000026295 · Cited by 34
Glucagon-like peptide-1 receptor agonists and safety in the preconception period
Minis, E., Stanford, F. C., & Mahalingaiah, S. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000835 · Cited by 34
Weight management strategies for patients with PCOS: current perspectives
Ozgen Saydam, B., & Yildiz, B. O. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1896966 · Cited by 33
Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-99622-4 · Cited by 35
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
“29 kg with 47 % of patients achieving a weight loss ≥ 5 % [23, 24].”
Metadata
- Authors
- Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., Xu, W., Mai, T., & Gong, Y.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2017-09-13
- Volume
- 87
- Issue
- 6
- Pages
- 767-774
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2747812115
- Cited by
- 148
- References
- 14
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- National Natural Science Foundation of China (No. 81200607)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.